[go: up one dir, main page]

CA2260886A1 - Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases - Google Patents

Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases Download PDF

Info

Publication number
CA2260886A1
CA2260886A1 CA002260886A CA2260886A CA2260886A1 CA 2260886 A1 CA2260886 A1 CA 2260886A1 CA 002260886 A CA002260886 A CA 002260886A CA 2260886 A CA2260886 A CA 2260886A CA 2260886 A1 CA2260886 A1 CA 2260886A1
Authority
CA
Canada
Prior art keywords
glycine
amino acid
alanine
serine
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002260886A
Other languages
English (en)
Inventor
Heinz Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2260886A1 publication Critical patent/CA2260886A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une méthode destinée au traitement prophylactique et/ou thérapeutique de la croissance tumorale et/ou des métastases, comprenant l'administration, à un être humain ou à un autre mammifère, d'un médicament ou d'une formulation nutritionnelle comportant au moins un acide aminé sélectionné dans le group constitué par la glycine, l'alanine, la sérine, et des sels de glycine physiologiquement acceptables, l'alanine et la sérine étant présentes en quantité efficace en vue de la prévention et/ou de l'inhibition de croissance tumorale et/ou des métastases. L'invention concerne également une méthode d'inhibition de la prolifération cellulaire accrue, comprenant l'administration, à un être humain ou à un autre mammifère, d'un médicament ou d'une formulation nutritionnelle comportant au moins un acide aminé sélectionné dans le groupe constitué par la glycine, l'alanine, la sérine, et des sels de glycine physiologiquement acceptables, l'alanine et la sérine étant présentes en quantité efficace en vue de l'inhibition de la prolifération cellulaire accrue.
CA002260886A 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases Abandoned CA2260886A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69047596A 1996-07-30 1996-07-30
US08/690,475 1996-07-30
PCT/EP1997/004124 WO1998004255A1 (fr) 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases

Publications (1)

Publication Number Publication Date
CA2260886A1 true CA2260886A1 (fr) 1998-02-05

Family

ID=24772606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260886A Abandoned CA2260886A1 (fr) 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases

Country Status (6)

Country Link
EP (1) EP0921794A1 (fr)
JP (1) JP2000515874A (fr)
AU (1) AU716906B2 (fr)
CA (1) CA2260886A1 (fr)
ID (1) ID19618A (fr)
WO (1) WO1998004255A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882451B1 (fr) * 1997-06-05 2004-05-12 Novartis Nutrition AG Glycine pour la prévention ou le traitement du rejet de greffes
KR100932520B1 (ko) * 2002-10-31 2009-12-17 박래옥 항암제 조성물
AU2005302173B2 (en) * 2004-11-02 2009-07-23 Oragenics, Inc. Methods for regulating weight and size of animals
KR20100015922A (ko) * 2007-03-26 2010-02-12 히로후미 마쓰이 암 환자용 수액 제제
TW201201713A (en) * 2010-04-05 2012-01-16 Abbott Lab Shelf stable nutritional liquids comprising beta alanine
JP5747183B2 (ja) * 2012-11-15 2015-07-08 株式会社日本生物製剤 抗癌剤
EP3016531A4 (fr) * 2013-07-01 2017-05-10 The Trustees Of Princeton University Compléments alimentaires et composition pour traiter le cancer
CN114947139A (zh) * 2022-04-28 2022-08-30 成都尚医信息科技有限公司 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB818170A (en) * 1957-12-30 1959-08-12 Edward Yerxa Domina Improvements in preparation for the treatment of non-tumorous prostatic hypertrophy
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS6248622A (ja) * 1985-08-28 1987-03-03 Grelan Pharmaceut Co Ltd 癌転移抑制剤
CA2097196C (fr) * 1991-10-07 1999-04-13 Shozo Aoi Preparation enterale pour le traitement du cancer
BR9607336A (pt) * 1995-02-23 1997-11-25 Novartis Nutrition Ag Composições de aminoácidos e utilidades das mesmas em nutrição clinica

Also Published As

Publication number Publication date
ID19618A (id) 1998-07-23
JP2000515874A (ja) 2000-11-28
AU3942097A (en) 1998-02-20
WO1998004255A1 (fr) 1998-02-05
AU716906B2 (en) 2000-03-09
EP0921794A1 (fr) 1999-06-16

Similar Documents

Publication Publication Date Title
CA2499199C (fr) Compositions nutritionnelles enrichies aux leucines
JP5145033B2 (ja) Ｈｍｂ組成物及びその使用
EP0810829B1 (fr) Compositions d'acides amines et leur utilisation dans la nutrition clinique
JP3908785B2 (ja) 微小循環の調節方法
JP3287842B2 (ja) 免疫刺激剤としてのアルギニンの用途
US10039732B2 (en) Nutritional composition for improving brain function in phenylketonuria
JPH031287B2 (fr)
US6096785A (en) Amino acid compositions and use thereof in treating renal dysfunction
AU716906B2 (en) Amino acid composition and use thereof in treating tumor growth and metastasis
WO1998032428A2 (fr) Compositions a base de choline et utilisation de la choline pour traiter les chocs endotoxiques
CA2227978A1 (fr) Immuno-modulation a l'aide d'amino-acides
JP3914585B2 (ja) マクロファージ一酸化窒素産生亢進剤
RU2335927C2 (ru) Обогащенные лейцином питательные композиции
JP3209375B2 (ja) アルコール性肝障害軽減剤
Welle Regulation by Metabolic Substrates
MXPA97006140A (en) Compositions of amino acids and the use of them in nutrition clin
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
FZDE Dead